In this proof‐of‐concept study, we report that Dyrk1 is a valid new target for AD treatment and show that its chronic inhibition reduced Aβ and tau pathology and ameliorated cognitive deficits in 3xTg‐AD mice. This evidence concerns the gene DYRK1A and Alzheimer disease.